X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

Novavax Covid-19 vaccine provides cross-protection against B.1.351 variant

Content Team by Content Team
11th May 2021
in Clinical Trials, News
Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The protein-based vaccine candidate NVX-CoV2373 is made from the genetic sequence of the first SARS-CoV-2 strain. It is adjuvanted with the company’s saponin-based Matrix-M to boost immune response and neutralising antibodies. The candidate proved to offer a high level of protection against B.1.351.

The randomised, observer-blinded, placebo-controlled Phase IIb trial assessed efficacy, safety and immunogenicity of the vaccine in healthy adult subjects and in a cohort of adults with human immunodeficiency virus who are medically stable.

Data showed that the trial met its primary endpoint. According to the initial primary analysis results, the vaccine candidate showed 49% overall efficacy and had an efficacy of 49% in the complete analysis, which is not published yet.

NVX-CoV2373 had 60% and 55% efficacy in the initial analysis and full analysis, respectively, in healthy adult subjects. Covid-19 cases observed during initial analysis were mostly mild-to-moderate and due to the south African B.1.351 variant.

Furthermore, previous infection with the original SARS-CoV-2 strain did not provide protection against B.1.351 variant infection during follow-up of 60 days.

The full trial analysis demonstrated a moderate protective effect of previous infection with original virus strain. Among placebo recipients, at 90 days of follow-up, the illness rate was 8% in baseline seronegative participants and 5.9% in baseline seropositive participants.

In the placebo group, the illness rate was 8% and 5.9% in baseline seronegative and seropositive subjects, respectively, at 90 days of follow up.

Novavax Research and Development (R&D) president Gregory Glenn said: “This data publication reinforces the encouraging safety profile and cross-protective effect across variants seen in studies of our vaccine to date.

“It also demonstrates that ongoing evaluation of Covid-19 vaccine efficacy against SARS-CoV-2 variants is urgently needed to inform vaccine development and use.”

 

Previous Post

Health Canada approves Pfizer and BioNTechs Covid-19 vaccine for adolescents

Next Post

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In